Cyclobenzaprine

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 342 publications

Superior Oblique Myokymia Treated with Cyclobenzaprine.

Superior Oblique Myokymia Treated with Cyclobenzaprine.

Journal: The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques

Published: March 27, 2026

Cyclobenzaprine Reimagined: Clinical Insights Into Tonmya for Fibromyalgia.

Cyclobenzaprine Reimagined: Clinical Insights Into Tonmya for Fibromyalgia.

Journal: The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians

Published: March 13, 2026

Steady-State Pharmacokinetic Properties of TNX-102 SL, a Sublingual Tablet Formulation of Cyclobenzaprine Hydrochloride (HCl), With Daily Dosing in Healthy Volunteers: A Randomized, Open-Label Trial.

Steady-State Pharmacokinetic Properties of TNX-102 SL, a Sublingual Tablet Formulation of Cyclobenzaprine Hydrochloride (HCl), With Daily Dosing in Healthy Volunteers: A Randomized, Open-Label Trial.

Journal: Clinical pharmacology in drug development

Published: January 30, 2026

Sublingual cyclobenzaprine (Tonmya) for fibromyalgia.

Sublingual cyclobenzaprine (Tonmya) for fibromyalgia.

Journal: The Medical letter on drugs and therapeutics

Published: January 08, 2026

Current evidence on TNX-102 SL (cyclobenzaprine HCl sublingual) for fibromyalgia: strengths, limitations, and emerging hypotheses.

Current evidence on TNX-102 SL (cyclobenzaprine HCl sublingual) for fibromyalgia: strengths, limitations, and emerging hypotheses.

Journal: Clinical rheumatology

Published: December 01, 2025

Efficacy and safety of TNX-102 SL in patients with fibromyalgia: a systematic review and meta-analysis.

Efficacy and safety of TNX-102 SL in patients with fibromyalgia: a systematic review and meta-analysis.

Journal: Pain management

Published: October 06, 2025

Sublingual Cyclobenzaprine: First Approval.

Sublingual Cyclobenzaprine: First Approval.

Journal: Clinical drug investigation

Published: October 06, 2025

Single-Dose Pharmacokinetic Assessment of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets): Results From Randomized, Open-Label Studies in Healthy Volunteers.

Single-Dose Pharmacokinetic Assessment of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets): Results From Randomized, Open-Label Studies in Healthy Volunteers.

Journal: Clinical pharmacology in drug development

Published: October 03, 2025

Paper-based reaction devices as accelerated platforms in forced degradation studies.

Paper-based reaction devices as accelerated platforms in forced degradation studies.

Journal: Journal of pharmaceutical sciences

Published: September 29, 2025

Tonmya (cyclobenzaprine hydrochloride sublingual tablets): first FDA-approved therapy for fibromyalgia in over 15 years.

Tonmya (cyclobenzaprine hydrochloride sublingual tablets): first FDA-approved therapy for fibromyalgia in over 15 years.

Journal: Annals of medicine and surgery (2012)

Published: September 10, 2025

Short-term efficacy and safety of sublingual cyclobenzaprine for fibromyalgia: A systematic review and meta-analysis.

Short-term efficacy and safety of sublingual cyclobenzaprine for fibromyalgia: A systematic review and meta-analysis.

Journal: Clinical rheumatology

Published: September 09, 2025

Efficacy and safety of interventions for Fibromyalgia syndrome comorbid with Irritable bowel syndrome: systematic review.

Efficacy and safety of interventions for Fibromyalgia syndrome comorbid with Irritable bowel syndrome: systematic review.

Journal: Clinical rheumatology

Published: August 21, 2025

Showing 1-12 of 342

Last Updated: 04/28/2026